Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the first quarter ended March 31, 2026.
Claritev, a healthcare technology, data, and insights company, today announced that Fernando Schwartz, Ph.D., Senior Vice President and Chief AI Officer, has been named to the DataIQ 100 North America list for 2026, recognizing leaders applying data and artificial intelligence to drive measurable impact across industries.
Claritev Corporation ("Claritev" or the "Company") (NYSE: CTEV), a healthcare technology, data, and insights company focused on making healthcare more transparent and affordable, today announced two cornerstone philanthropic initiatives as a part of Claritev Cares™, a new charitable foundation.
Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced that members of its management team will meet with investors at the following investor events in March 2026:
Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, will host its 2026 Investor Day on Monday, March 16, 2026 at the New York Stock Exchange. The event will feature presentations by members of Claritev’s management team discussing the company’s long term growth strategy, vertical markets, product roadmap, and financial outlook, along with conversations with a number of clients and partners. The event and a live webcast will begin at 1:00 p.m. ET.
Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, announced today that it will release its fourth quarter and fiscal year 2025 financial results after market close on Monday, February 23, 2026, and hold a conference call at 4:30 pm Eastern Time.
Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent, and fair for all, today announced a strategic relationship with Kinetiq Health, a healthcare risk management organization specializing in claims surveillance, diagnostic certainty, and cost intervention strategies.
Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. Management will be presenting on Thursday, January 15, 2026 at 7:30 a.m. PT. A live webcast and audio archive of the presentation will be available through the investor relations section of Claritev’s website at investors.claritev.com/events-and-presentations. For one-on-one meetings, please contact a representative at the host firm.
Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced that members of its management team will participate in person at the following conferences in December 2025:
Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced the pricing of an underwritten public offering (the “Offering”) of 1,500,000 shares of its Class A common stock, par value $0.0001 per share (the “Class A common stock”), by certain affiliates of Hellman & Friedman (collectively, the “Selling Stockholders”) at a price to the public of $51.50 per share. The Selling Stockholders granted the underwriters a 30-day option to purchase up to an additional 225,000 shares of Class A common stock. The underwriters propose to offer the shares of Class A common stock to the public at a fixed price, which may be changed at any time without notice. Claritev will not sell any shares of its Class A common stock in the Offering and will not receive any proceeds from the sale of the shares of Class A common stock being offered by the Selling Stockholders. The Offering is expected to close by November 14, 2025, subject to customary closing conditions.
Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced the commencement of an underwritten public offering (the “Offering”) of 1,500,000 shares of its Class A common stock, par value $0.0001 per share (the “Class A common stock”), by certain affiliates of Hellman & Friedman (collectively, the “Selling Stockholders”). The Selling Stockholders granted the underwriters a 30-day option to purchase up to an additional 225,000 shares of Class A common stock. The underwriters propose to offer the shares of Class A common stock to the public at a fixed price, which may be changed at any time without notice. Claritev will not sell any shares of its Class A common stock in the Offering and will not receive any proceeds from the sale of the shares of Class A common stock being offered by the Selling Stockholders. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed.
Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the third quarter ended September 30, 2025.
